Huadong Medicine Co (SZSE:000963) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Huadong Medicine Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Huadong Medicine Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Huadong Medicine Co's long-term debt to total assets ratio declined from Sep. 2023 (0.03) to Sep. 2024 (0.00). It may suggest that Huadong Medicine Co is progressively becoming less dependent on debt to grow their business.

Huadong Medicine Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Huadong Medicine Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huadong Medicine Co LT-Debt-to-Total-Asset Chart

Huadong Medicine Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.04

0.02

Huadong Medicine Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.02	0.02	-	-

Huadong Medicine Co LT-Debt-to-Total-Asset Calculation

Huadong Medicine Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	577.455	/	33509.362
	=	0.02

Huadong Medicine Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	156.759	/	37495.254
	=	0.00

Huadong Medicine Co (SZSE:000963) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Huadong Medicine Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Huadong Medicine Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Huadong Medicine Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huadong Medicine Co Ltd (SZSE:000963) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

468 Yan’an Road, Floor 7, 9 and 10, Gate No. 1, Building No. 1, Hangzhou, CHN, 310006

Website

http://www.eastchinapharm.com

Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.

Executives

He Ru Fen	Supervisors
Hu Bao Zhen	Supervisors
Zhou Shun Hua	Executives
Shao Ling Min	Supervisors
Wan Ling Ling	Executives
Fu Hang	Director
Yue Jin	Director
Chen Bo	Secretary Dong
Qin Yun	Supervisors
Li Bang Liang	Directors, executives
Zhou Jin Bao	Directors, executives

Huadong Medicine Co Headlines

No Headlines